Navigation Links
Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b
Date:9/1/2008

MUNICH, Germany, Sept. 2 /PRNewswire-FirstCall/ -- Data presented today at the Annual Congress of the European Society of Cardiology showed that the investigational oral Factor Xa inhibitor DU-176b reduced the incidence of venous thromboembolism (VTE) compared with dalteparin among patients undergoing elective unilateral hip replacement surgery. There was a statistically significant dose response in efficacy (P <0.01), and the observed bleeding rates were low across the groups. DU-176b is being developed solely by Daiichi Sankyo Company, Limited (TSE: 4568) and the data were presented by lead investigator Dr. Gary Raskob.

This randomized, double-blind comparative study examined the safety and efficacy of four doses of DU-176b (15, 30, 60 and 90 mg once daily) versus the low molecular weight heparin, dalteparin. The study was conducted among 903 patients in Europe and North America undergoing total hip replacement surgery.

"These findings are encouraging and we look forward to further study on this Factor Xa inhibitor," said Gary Raskob, Ph.D., Dean, College of Public Health at the University of Oklahoma Health Sciences Center. "These findings indicate DU-176b may provide a high degree of efficacy, but further study is needed."

"As the company that discovered one of the first Factor Xa small molecules (DX-9065a), we are proud to be building on our innovation in cardiovascular disease and tackling the need for better and more effective ways to prevent thrombosis," said John Alexander M.D., president, Daiichi Sankyo Pharma Development. "We expect to commence phase III studies for DU-176b, targeting patients with atrial fibrillation, before the end of 2008.

Study Result Details

VTE incidence (%) Bleeding occurrence*** (%)

Dalteparin 43.8 [35.5-52.3]# 0 [0-2.1]

DU-176b 15mg 28.2 [21.6-35.6]* 1.6 [0.3-4.5]

30mg 21.2 [15.0-28.
'/>"/>

SOURCE Daiichi Sankyo
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
2. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
3. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
4. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... and LYON, France , Dec. 19, ... LLY ) and Adocia (Euronext Paris: FR0011184241 – ADOC) ... an ultra-rapid insulin, known as BioChaperone Lispro, for treatment ... BioChaperone Lispro relies on Adocia,s proprietary BioChaperone® technology and ... and Adocia will develop BioChaperone Lispro with the goal ...
(Date:12/17/2014)... , Dec. 17, 2014  Strategic Health Services, Inc. ... solutions, today announced a strategic agreement with QualCare, Inc., a ... New Jersey regional marketplace.  This agreement will ... health and wellness solutions QualCare brings to its clients ... surrounding region. QualCare plans cover more ...
(Date:12/17/2014)... , Dec. 17, 2014  ImmunoCellular Therapeutics, ... US Patent and Trademark Office (USPTO) has issued ... a dendritic cell-based immunotherapeutic vaccine targeting six tumor ... claims of US Patent No. 8,871,211, which issued ... cancer by administering a dendritic cell composition comprising ...
Breaking Medicine Technology:Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 2Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2
... 2011 Reportlinker.com announces that a ... in its catalogue: ... Global Markets ... HIGHLIGHTS * The ...
... The Commonwealth on Wednesday welcomed a ... global action against the burden and debilitating impact of ... Commonwealth priorities as identified by Health Ministers at their ... Priority for the Commonwealth". The High-Level  Meeting ...
Cached Medicine Technology:Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets 2Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets 3Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets 4Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets 5Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets 6Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets 7Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets 8Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets 9Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets 10Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets 11Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets 12Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets 13Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets 14Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets 15Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets 16Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets 17Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets 18Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets 19Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets 20Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets 21Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets 22Commonwealth Welcomes Global Commitment to Combat Non-Communicable Diseases 2
(Date:12/21/2014)... BellasDress.com offers a wide range of women’s dresses, ... its BellasDress Christmas Sale , offering big discounts ... BellasDress is a famous online supplier of women’s dresses; ... series of promotions. The dress experts of the company ... are proud of offering high quality wedding dresses and ...
(Date:12/21/2014)... York, New York (PRWEB) December 21, 2014 ... ) and other product liability claims involving a ... incretin mimetics continue to move forward in a ... Court, Southern District of California, Bernstein Liebhard LLP ... the Court has established a data cut-off date ...
(Date:12/21/2014)... Muskegon, Mi (PRWEB) December 21, 2014 ... a child in need while at the same time helping ... is a non-profit community-based organization committed to serving those ... to meet their needs to improve the quality of life. ... would make an impact in the local community and he ...
(Date:12/21/2014)... Portland, OR (PRWEB) December 21, 2014 ... discussing some of the issues and systemic barriers for ... ITU World Paratriathlon Champion. Scheidies has a condition called ... over time. He describes how he adapted his athletic ... to use his success in triathlon to pioneer the ...
(Date:12/21/2014)... (PRWEB) December 21, 2014 The Oncology Institute ... in the Santa Ana and Whittier offices. The Hope for ... the lives of patients and their families during the holiday ... out to approximately 70 children between both offices. This event ... help of Target’s community service team, store managers and assistant ...
Breaking Medicine News(10 mins):Health News:BellasDress.com Announces its BellasDress Christmas Sale 2Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 2Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 3Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 4Health News:AlignLife of Norton Shores Makes a Brighter Christmas for Kids in Muskegon 2Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 2Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 3
... Hawaiians Access to Nursing Home, Assisted Living, Home Care and ... StatewideRICHMOND, Va., April 30 The cost of long term ... putting significant financial pressure on those in or near retirement, ... the same time, the current economic downturn has led to ...
... EPS (1) was $0.42 -- Annual Guidance Narrowed to $2.05 to $2.18 Adjusted Diluted EPS(1) - ... Inc. (NYSE: WST ) today announced its results for the first quarter of 2009. ... Three Months Ended, ... March 31, ...
... - Nuvo Research Inc. (TSX: NRI), a Canadian drug development ... that are delivered to and through the skin using its ... and operational results for the quarter ended March 31, 2009., ... Successfully completed all Pennsaid(R) studies necessary to resubmit, ...
... 2009 Performance Outlook -MELVILLE, N.Y., April 30 Gentiva Health ... of comprehensive home health services, today reported the following 2009 ... Net revenues of $288.9 ... $321.6 million, which included net revenues of $77.8 million from ...
... SUNNYVALE, Calif., April 30 Cepheid (Nasdaq: CPHD ) ... investor conferences, and invited investors to participate via webcast., ... York, NY, Wednesday, May 13, 2009 at 10.40 ... Boston, MA, Tuesday, May 19, 2009 at 8.50 ...
... ... ------- ... $4,150 $4,863 (15%), (Loss) / Income ... ($5.40) $0.56, Special Items ...
Cached Medicine News:Health News:Growth in Hawaii Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 2Health News:Growth in Hawaii Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 3Health News:Growth in Hawaii Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 4Health News:West Announces First Quarter 2009 Results 2Health News:West Announces First Quarter 2009 Results 3Health News:West Announces First Quarter 2009 Results 4Health News:West Announces First Quarter 2009 Results 5Health News:West Announces First Quarter 2009 Results 6Health News:West Announces First Quarter 2009 Results 7Health News:West Announces First Quarter 2009 Results 8Health News:West Announces First Quarter 2009 Results 9Health News:West Announces First Quarter 2009 Results 10Health News:West Announces First Quarter 2009 Results 11Health News:West Announces First Quarter 2009 Results 12Health News:West Announces First Quarter 2009 Results 13Health News:West Announces First Quarter 2009 Results 14Health News:West Announces First Quarter 2009 Results 15Health News:West Announces First Quarter 2009 Results 16Health News:West Announces First Quarter 2009 Results 17Health News:West Announces First Quarter 2009 Results 18Health News:Nuvo announces 2009 first quarter financial results 2Health News:Nuvo announces 2009 first quarter financial results 3Health News:Nuvo announces 2009 first quarter financial results 4Health News:Nuvo announces 2009 first quarter financial results 5Health News:Nuvo announces 2009 first quarter financial results 6Health News:Nuvo announces 2009 first quarter financial results 7Health News:Nuvo announces 2009 first quarter financial results 8Health News:Nuvo announces 2009 first quarter financial results 9Health News:Nuvo announces 2009 first quarter financial results 10Health News:Nuvo announces 2009 first quarter financial results 11Health News:Gentiva Reports First Quarter 2009 Results 2Health News:Gentiva Reports First Quarter 2009 Results 3Health News:Gentiva Reports First Quarter 2009 Results 4Health News:Gentiva Reports First Quarter 2009 Results 5Health News:Gentiva Reports First Quarter 2009 Results 6
10 L, Bulk Recommended for 2, 5, 10 L pipettes....
This extended 10 ul combats contamination by keeping your pipettor out of 1.5 ul and 2.0 ul tubes. Utilizes MicroPoint design and 2 ul reference mark....
... the gold standard for WBC differentials, ... your technologists manual results- no doubts, ... morphology advances cell separation to a ... differentiation of various disease states, including ...
200 L, Racked, Pre-sterilized, 96 tips/rack Recommended for 20, 25, 50, 100 and 200 L pipettes. Can also be used with 300 L pipettes when pipetting 200 L or less....
Medicine Products: